SEC Comment Letter for Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654) (ORKA) — May 14, 2020
Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654)
Date: May 14, 2020 · CIK: 0000907654 · Accession: 0000000000-20-004302
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238067
Letter
United States securities and exchange commission logo May 14, 2020 Michael Bristow, M.D. President ARCA biopharma, Inc. 11080 Circle Point Road, Suite 140 Westminster, CO 80020 Re:ARCA biopharma, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238067 Dear Dr. Bristow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brent Fassett, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2020
Michael Bristow, M.D.
President
ARCA biopharma, Inc.
11080 Circle Point Road, Suite 140
Westminster, CO 80020
Re:ARCA biopharma, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238067
Dear Dr. Bristow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brent Fassett, Esq.